# Tecogen Inc.: financial statements, quarterly

TGEN · NYSE · CIK 1537435 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/tgen.md) · [Financials](/companies/tgen/financials.md) · [Filings](/companies/tgen/filings.md) · [Insiders](/companies/tgen/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/tgen/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $k | [7,113](/filings/0001537435-24-000121.md) | [5,898 d](/filings/0001537435-25-000018.md) | [6,186](/filings/0001537435-25-000037.md) | [4,728](/filings/0001537435-25-000131.md) | [5,630](/filings/0001537435-25-000143.md) | [6,076 d](/filings/0001537435-26-000013.md) | [7,278](/filings/0001537435-26-000038.md) | [7,295](/filings/0001537435-26-000066.md) | [7,183](/filings/0001537435-25-000143.md) | [5,318 d](/filings/0001537435-26-000013.md) | [6,336](/filings/0001537435-26-000038.md) | [5,746](/filings/0001537435-26-000066.md) |
| Cost of revenue | $k | [4,187](/filings/0001537435-24-000121.md) | [3,549 d](/filings/0001537435-25-000018.md) | [3,610](/filings/0001537435-25-000037.md) | [2,649](/filings/0001537435-25-000131.md) | [3,149](/filings/0001537435-25-000143.md) | [3,341 d](/filings/0001537435-26-000013.md) | [4,057](/filings/0001537435-26-000038.md) | [4,832](/filings/0001537435-26-000066.md) | [5,000](/filings/0001537435-25-000143.md) | [3,361 d](/filings/0001537435-26-000013.md) | [3,746](/filings/0001537435-26-000038.md) | [3,572](/filings/0001537435-26-000066.md) |
| Gross profit | $k | [2,926](/filings/0001537435-24-000121.md) | [2,349 d](/filings/0001537435-25-000018.md) | [2,576](/filings/0001537435-25-000037.md) | [2,079](/filings/0001537435-25-000131.md) | [2,481](/filings/0001537435-25-000143.md) | [2,734 d](/filings/0001537435-26-000013.md) | [3,221](/filings/0001537435-26-000038.md) | [2,462](/filings/0001537435-26-000066.md) | [2,184](/filings/0001537435-25-000143.md) | [1,957 d](/filings/0001537435-26-000013.md) | [2,590](/filings/0001537435-26-000038.md) | [2,174](/filings/0001537435-26-000066.md) |
| Research and development | $k | [160](/filings/0001537435-24-000121.md) | [214 d](/filings/0001537435-25-000018.md) | [255](/filings/0001537435-25-000037.md) | [246](/filings/0001537435-25-000131.md) | [234](/filings/0001537435-25-000143.md) | [227 d](/filings/0001537435-26-000013.md) | [293](/filings/0001537435-26-000038.md) | [269](/filings/0001537435-26-000066.md) | [298](/filings/0001537435-25-000143.md) | [307 d](/filings/0001537435-26-000013.md) | [364](/filings/0001537435-26-000038.md) | [320](/filings/0001537435-26-000066.md) |
| Selling, general and administrative | $k | [3,294](/filings/0001537435-23-000148.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $k | [(368)](/filings/0001537435-24-000121.md) | [(1,815) d](/filings/0001537435-25-000018.md) | [(1,050)](/filings/0001537435-25-000037.md) | [(1,474)](/filings/0001537435-25-000131.md) | [(873)](/filings/0001537435-25-000143.md) | [(1,137) d](/filings/0001537435-26-000013.md) | [(594)](/filings/0001537435-26-000038.md) | [(1,412)](/filings/0001537435-26-000066.md) | [(2,101)](/filings/0001537435-25-000143.md) | [(4,138) d](/filings/0001537435-26-000013.md) | [(2,136)](/filings/0001537435-26-000038.md) | [(2,150)](/filings/0001537435-26-000066.md) |
| Interest expense | $k | [6.4](/filings/0001537435-23-000148.md) | [7.4 d](/filings/0001537435-24-000022.md) | [18.7](/filings/0001537435-24-000063.md) | [17.9](/filings/0001537435-24-000106.md) | [23.0](/filings/0001537435-25-000143.md) | [30.8 d](/filings/0001537435-26-000013.md) | [32.3](/filings/0001537435-26-000038.md) | [38.2](/filings/0001537435-26-000066.md) | [41.1](/filings/0001537435-25-000143.md) | [38.7 d](/filings/0001537435-26-000013.md) | [34.2](/filings/0001537435-26-000038.md) | [39.2](/filings/0001537435-26-000066.md) |
| Net income | $k | [(482)](/filings/0001537435-24-000121.md) | [(1,846) d](/filings/0001537435-25-000018.md) | [(1,105)](/filings/0001537435-25-000037.md) | [(1,539)](/filings/0001537435-25-000131.md) | [(930)](/filings/0001537435-25-000143.md) | [(1,186) d](/filings/0001537435-26-000013.md) | [(660)](/filings/0001537435-26-000038.md) | [(1,464)](/filings/0001537435-26-000066.md) | [(2,131)](/filings/0001537435-25-000143.md) | [(3,994) d](/filings/0001537435-26-000013.md) | [(2,121)](/filings/0001537435-26-000038.md) | [(2,149)](/filings/0001537435-26-000066.md) |
| Diluted EPS | $ per share | [(0.02)](/filings/0001537435-24-000121.md) | not reported | [(0.04)](/filings/0001537435-25-000037.md) | [(0.06)](/filings/0001537435-25-000131.md) | [(0.04)](/filings/0001537435-25-000143.md) | not reported | [(0.03)](/filings/0001537435-26-000038.md) | [(0.06)](/filings/0001537435-26-000066.md) | [(0.07)](/filings/0001537435-25-000143.md) | not reported | [(0.07)](/filings/0001537435-26-000038.md) | [(0.07)](/filings/0001537435-26-000066.md) |
| Basic EPS | $ per share | [(0.02)](/filings/0001537435-24-000121.md) | not reported | [(0.04)](/filings/0001537435-25-000037.md) | [(0.06)](/filings/0001537435-25-000131.md) | [(0.04)](/filings/0001537435-25-000143.md) | not reported | [(0.03)](/filings/0001537435-26-000038.md) | [(0.06)](/filings/0001537435-26-000066.md) | [(0.07)](/filings/0001537435-25-000143.md) | not reported | [(0.07)](/filings/0001537435-26-000038.md) | [(0.07)](/filings/0001537435-26-000066.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [0.6](/filings/0001537435-23-000148.md) | [1.4](/filings/0001537435-25-000018.md) | [1.5](/filings/0001537435-24-000063.md) | [0.8](/filings/0001537435-24-000106.md) | [1.3](/filings/0001537435-24-000121.md) | [5.4](/filings/0001537435-26-000013.md) | [4.1](/filings/0001537435-25-000037.md) | [1.6](/filings/0001537435-25-000131.md) | [15.3](/filings/0001537435-25-000143.md) | [12.4](/filings/0001537435-26-000066.md) | [9.3](/filings/0001537435-26-000038.md) | [6.8](/filings/0001537435-26-000066.md) |
| Current assets | $m | [21.6](/filings/0001537435-23-000148.md) | [20.3](/filings/0001537435-25-000018.md) | [19.7](/filings/0001537435-24-000063.md) | [18.1](/filings/0001537435-24-000106.md) | [18.2](/filings/0001537435-24-000121.md) | [22.1](/filings/0001537435-26-000013.md) | [20.6](/filings/0001537435-25-000037.md) | [19.0](/filings/0001537435-25-000131.md) | [32.1](/filings/0001537435-25-000143.md) | [28.9](/filings/0001537435-26-000066.md) | [26.5](/filings/0001537435-26-000038.md) | [24.0](/filings/0001537435-26-000066.md) |
| Total assets | $m | [29.2](/filings/0001537435-24-000121.md) | [27.8](/filings/0001537435-25-000018.md) | [28.5](/filings/0001537435-25-000037.md) | [27.2](/filings/0001537435-25-000131.md) | [27.5](/filings/0001537435-25-000143.md) | [31.1](/filings/0001537435-26-000013.md) | [29.7](/filings/0001537435-26-000038.md) | [28.4](/filings/0001537435-26-000066.md) | [41.5](/filings/0001537435-25-000143.md) | [37.0](/filings/0001537435-26-000066.md) | [34.5](/filings/0001537435-26-000038.md) | [31.6](/filings/0001537435-26-000066.md) |
| Current liabilities | $m | [10.1](/filings/0001537435-23-000148.md) | [10.5](/filings/0001537435-25-000018.md) | [11.2](/filings/0001537435-24-000063.md) | [11.5](/filings/0001537435-24-000106.md) | [11.8](/filings/0001537435-24-000121.md) | [16.8](/filings/0001537435-26-000013.md) | [14.9](/filings/0001537435-25-000037.md) | [14.0](/filings/0001537435-25-000131.md) | [11.8](/filings/0001537435-25-000143.md) | [9.3](/filings/0001537435-26-000066.md) | [8.8](/filings/0001537435-26-000038.md) | [8.2](/filings/0001537435-26-000066.md) |
| Total liabilities | $m | [12.8](/filings/0001537435-23-000148.md) | [13.1](/filings/0001537435-25-000018.md) | [14.8](/filings/0001537435-24-000063.md) | [15.1](/filings/0001537435-24-000106.md) | [16.3](/filings/0001537435-24-000121.md) | [21.0](/filings/0001537435-26-000013.md) | [20.2](/filings/0001537435-25-000037.md) | [19.4](/filings/0001537435-25-000131.md) | [16.1](/filings/0001537435-25-000143.md) | [15.5](/filings/0001537435-26-000066.md) | [14.9](/filings/0001537435-26-000038.md) | [14.1](/filings/0001537435-26-000066.md) |
| Shareholders' equity | $m | [16.5](/filings/0001537435-23-000148.md) | [14.7](/filings/0001537435-25-000018.md) | [13.7](/filings/0001537435-24-000063.md) | [12.2](/filings/0001537435-24-000106.md) | [11.3](/filings/0001537435-24-000121.md) | [10.2](/filings/0001537435-26-000013.md) | [9.6](/filings/0001537435-25-000037.md) | [9.1](/filings/0001537435-25-000131.md) | [25.5](/filings/0001537435-25-000143.md) | [21.6](/filings/0001537435-26-000066.md) | [19.7](/filings/0001537435-26-000038.md) | [17.7](/filings/0001537435-26-000066.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(1,174) d](/filings/0001537435-24-000121.md) | [202 d](/filings/0001537435-25-000018.md) | [248](/filings/0001537435-25-000037.md) | [(158) d](/filings/0001537435-25-000131.md) | [(207) d](/filings/0001537435-25-000143.md) | [4,178 d](/filings/0001537435-26-000013.md) | [(1,173)](/filings/0001537435-26-000038.md) | [(2,602) d](/filings/0001537435-26-000066.md) | [(3,561) d](/filings/0001537435-25-000143.md) | [(2,575) d](/filings/0001537435-26-000013.md) | [(3,108)](/filings/0001537435-26-000038.md) | [(2,353) d](/filings/0001537435-26-000066.md) |
| Capital expenditure | $k | [12.1 d](/filings/0001537435-24-000121.md) | [15.1 d](/filings/0001537435-25-000018.md) | [105](/filings/0001537435-25-000037.md) | [452 d](/filings/0001537435-25-000131.md) | [282 d](/filings/0001537435-25-000143.md) | [130 d](/filings/0001537435-26-000013.md) | [132](/filings/0001537435-26-000038.md) | [146 d](/filings/0001537435-26-000066.md) | [75.3 d](/filings/0001537435-25-000143.md) | [47.5 d](/filings/0001537435-26-000013.md) | [46.1](/filings/0001537435-26-000038.md) | [73.3 d](/filings/0001537435-26-000066.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [24.9](/filings/0001537435-23-000148.md) | [24.9](/filings/0001537435-24-000063.md) | [24.9](/filings/0001537435-24-000106.md) | [24.9](/filings/0001537435-24-000121.md) | [24.9](/filings/0001537435-25-000037.md) | [24.9](/filings/0001537435-25-000131.md) | [24.9](/filings/0001537435-25-000143.md) | [25.0](/filings/0001537435-26-000038.md) | [25.3](/filings/0001537435-26-000066.md) | [28.8](/filings/0001537435-25-000143.md) | [29.9](/filings/0001537435-26-000038.md) | [30.0](/filings/0001537435-26-000066.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,187,822 at 2026-08-13, from the cover of the [10-Q filed 2026-08-13](/filings/0001537435-26-000066.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:42 ET. No prices; not investment advice.